Sibiu

• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending
  2024-519994-20-00 5 Agitation Associated with Alzheimer’s Disease
• A study for adolescents who are depressed and thinking of suicide Recruiting
  2024-518615-19-00 5 2026-04-22 Major Depressive Disorder
• A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici … Recruiting
  2024-516792-32-01 4 2025-07-18 Metastatic non-squamous non-small cell lung cancer
• A study to assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia Recruiting
  2024-515451-38-00 5 2025-02-27 Primary Immune thrombocytopenia (ITP)
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla … Recruiting
  2023-507746-83-00 5 2024-11-27 Generalized Myasthenia Gravis
• Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting
  2023-503523-25-00 4 2024-02-29 Non-small cell lung cancer
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) … Recruiting
  2022-501100-94-00 5 2023-11-08 Episodic Migraine
• A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared … Recruiting
  2022-500257-16-00 5 2023-03-17 Diabetic Foot Infections
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08 Obesity
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D … Recruiting
  2025-523123-22-00 5 2026-05-07 Chronic Kidney Disease
• Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting
  2025-523974-18-00 5 2026-04-30 Obesity
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI) Recruiting
  2025-522514-23-00 5 2026-02-12 Urinary Incontinence
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2025-521382-27-00 10 2025-12-04 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant … Recruiting
  2024-516794-70-00 4 2025-11-03 Metastatic non-squamous non-small cell lung cancer
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520613-31-00 5 2025-10-31 Agitation Associated with Alzheimer’s Disease
• Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of NSCLC Recruiting
  2024-519883-42-00 5 2025-10-08 Non-small cell lung cancer
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung … Recruiting
  2024-517780-24-00 5 2025-09-18 Lung Cancer
• A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination wi … Recruiting
  2024-519945-31-00 5 2025-08-21 Type 1 Diabetes
• A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease Recruiting
  2024-513035-25-00 4 2025-07-11 Psychosis associated with Alzheimer’s Disease
• A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patient … Recruiting
  2023-510026-32-00 5 2025-06-11 Generalized Myasthenia Gravis
• Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting
  2024-514465-18-00 9 2025-04-23 Advanced or Metastatic Non-Squamous NSCLC

Showing 1–24 of 55 trials